 |
 |
 |
 |
 |
These two menacing viruses have several things in common that make their presence in the body at the same time (commonly called “co-infection”) very likely. Their mode of transmission, i.e. the way they are transmitted, via contact of the blood of a healthy person with that of contaminated blood is the same for both the Hec C virus and the HIV virus.
According to the CDC, the incidence of co-infection is relatively high. In the USA almost 1 out of 4 people infected with HIV virus is also infected with Hepatitis C virus, and the numbers increase dramatically if the infected person is involved with illicit injected drugs.
Interferon is a protein that is naturally produced in the body. Recently some research has shown that interferon has influence over the growth and function of certain cells, especially those related to the body’s immune system which helps the body to fight against certain infections and disease processes.
This protein has been synthesized and is now available as a prescription medication under the generic name of Interferon Alfa 2-b and is used for the treatment of many diseases including the cancer and various types of viral hepatitis including the hepatitis C virus.
Pegasys® (peginterferon alfa-2a)
is a once-a-week self injectable medication approved by the U.S. Food and Drug Administration to treat adults who have a chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) who show clinical signs of liver damage with no prior treatment with interferon. Read more about Pegasys
Daklinza® (daclatasvir)
for Treatment of Chronic Hepatitis C in the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza® (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus Read more about Daklinza
Hepcinat (Sofosbuvir)
is a breakthrough treatment for Hepatitis C infections. Its mechanism of action involves inhibiting the enzyme which is necessary for the virus if it is to multiply. A complete cure may even be possible. Chronic hepatitis C is a serious infection of the liver Read more about Hepcinat
Galexos (Simeprevir)
is a medication used to treat Hep C. It is used in combination with other medications to cure people of the Hep C virus. It is approved in Canada for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin in adults with compensated liver disease, including cirrhosis Read more about Galexos
OLYSIO
is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen with peginterferon-alfa and ribavirin (P/R), in HCV genotype 1 (G1) infected subjects with compensated liver disease (including cirrhosis). Read more about Olysio
Sovaldi
is a once-daily oral nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen. Gilead states that it must be used with ribavirin or in combination with peginterferon alfa and ribavirin. Read more about Sovaldi
HARVONI
the first once-daily single tablet regimen for the treatment of chronic hepatitis C genotype 1 infection in adults. Gilead reports that the majority of patients can be cured with a once-daily pill in a period of 8 to 12 weeks. Read more about Harvoni
VIEKIRA PAK™
is an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis. VIEKIRA PAK is the only FDA-approved regimen that contains three distinct mechanisms of action Read More About Viekira Pak